Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02802176
Other study ID # IRB 166094
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date August 25, 2022

Study information

Verified date June 2023
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate implantation rate with intra-vaginal culture (IVC) with the INVOcell device versus traditional In-Vitro Fertilization (IVF) while using minimal stimulation protocols


Description:

This is a Phase IV, single center randomized controlled trial evaluating intra-vaginal culture (IVC) using INVOcell versus traditional In-Vitro Fertilization (IVF) using oral stimulation or minimal gonadotropin stimulation protocols. The pilot aims to includes 40 women who will be randomized to either the intra-vaginal culture group (N=20) using INVOcell or to the traditional IVF group (N=20). Primary aim is implantation rate, which is defined by number gestational sacs seen on early pregnancy ultrasound divided by number of embryos transferred. Secondary aims are: - Embryo quality, which is measured by system similar to the Gardner grading system at cleavage stage. Reported quality will be converted to the simplified SART embryo scoring system which provides an overall categorical embryo grade of "Good", "Fair" or "Poor". - Fertilization rate, which is defined by the total number of fertilized oocytes divided by total number of mature oocytes retrieved. This comparison will take place on day-3, as that is when the IVC embryos will be assessed. - Clinical pregnancy rate, which is defined by the number of fetal poles with heartbeat seen on ultrasound divided by the number of embryos transferred. - Live birth rate, which is defined by the number of living babies delivered divided by the number of transfers


Recruitment information / eligibility

Status Terminated
Enrollment 39
Est. completion date August 25, 2022
Est. primary completion date April 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 37 Years
Eligibility Inclusion Criteria: - Normal uterine cavity - One or more years of infertility - Normal male partner semen analysis Exclusion Criteria: - Age <18 years old or >37 years old - Antral Follicle Count (AFC) <8 - Abnormal male partner semen analysis or use of donor sperm - Vaginal inflammation or genital (vaginal, uterine, tubal) infection - Uncontrolled chronic disease (such as uncontrolled diabetes or hypertension) - Uterine anatomic abnormalities - Allergy to plastics or inability to use diaphragm retention device - Untreated hydrosalpinx - Current alcohol abuse (defined by >14 drinks/week) - Prior history of IVF cycle where fertilization did not occur - History of recurrent pregnancy loss

Study Design


Related Conditions & MeSH terms


Intervention

Device:
INVOcell device
intra-vaginal culture of embryos using INVOcell device
Other:
Traditional IVF
traditional culture of embryos in-vitro

Locations

Country Name City State
United States University of California San Francisco - Center for Reproductive Health San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Implantation Rate defined by number gestational sacs seen on early pregnancy ultrasound typically done at 6 weeks of gestational age divided by number of embryos transferred approximately 4 weeks following randomization. Clinically this is typically done around 6 weeks of gestational age
Secondary Embryo Quality -Embryo quality, which is measured by system similar to the Gardner grading system at cleavage stage. Reported quality will be converted to the simplified SART embryo scoring system which provides an overall categorical embryo grade of "Good", "Fair" or "Poor". measured after 3 days of incubation
Secondary Fertilization Rate defined by the total number of fertilized oocytes divided by total number of mature oocytes retrieved measured after 3 days of incubation
Secondary Clinical Pregnancy Rate which is defined by the number of fetal poles with heartbeat seen on early pregnancy ultrasound typically done at 6 weeks of gestational age divided by the number of embryos transferred approximately 4 weeks following randomization. Clinically this is typically done around 6 weeks of gestational age
Secondary Live Birth Rate which is defined by the number of living babies delivered divided by the number of transfers 9 months after embryo transfer
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A